Emerging Companies Give Region Strong Base to Transform Global Healthcare
To help Asia-Pacific emerging biopharmaceutical companies achieve their
growth aspirations, Quintiles today launched a new solution set tailored
to meet the needs of emerging companies in the world’s most diverse and
dynamic healthcare market.
“Asia-Pacific is poised to become the world’s next biopharma powerhouse,
not least because of its growing number of emerging companies with
promising pipelines,” said Senior Vice President Ross Horsburgh, M.D.,
Quintiles Head of Clinical Development, Asia-Pacific. “These companies
face formidable challenges as they look to expand into markets or
therapeutic areas in which they may have limited or no experience.
“From start-ups to larger emerging players, our Asia-Pac solution is
designed to improve their probability of success, whether their growth
aspirations are regional or global.”
The Quintiles Asia-Pacific Emerging Biopharma solution includes:
Dedicated local project leadership based in Asia-Pac with
knowledge of local markets, customs and language.
Custom-tailored operational models to meet individual customer
priorities and use Quintiles’ world-class processes and platforms.
Accelerated patient recruitment through our global network of
25 Prime and >1,200 Partner sites – with seven of those Prime Sites
located in Asia-Pacific.
The Asia-Pacific solution gives emerging companies access to Quintiles’
data-driven insights; its knowledge of local markets; its in-depth
therapeutic and scientific expertise; and its global drug development
platform. It further adds to Quintiles’ solutions for emerging
companies, which includes Novella Clinical, a specialty CRO focused on
the needs of small to mid-sized oncology companies and medical device
and diagnostic companies.
Quintiles is a recognized as an industry leader
in Phase I and Phase
II/III research among emerging biopharma customers. Since 2011
Quintiles has worked on more than 60 studies involving almost 20,000
patients for Asia-Pacific emerging companies. Quintiles is the
recognized industry leader in the region, having won BioPharma Asia’s
“Best CRO in Asia” award three times in the event’s five-year history,
and in 2014 – for the sixth time in eight years – honored as
Asia-Pacific CRO of the Year by Frost & Sullivan, a leading business
research and consulting firm.
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical
development and commercial outsourcing services conducting business in
approximately 100 countries. We have helped develop or commercialize all
of the top-75 best-selling drugs on the market. Quintiles applies the
breadth and depth of our service offerings along with extensive
therapeutic, scientific and analytics expertise to help our customers
navigate an increasingly complex healthcare environment as they seek to
improve efficiency and effectiveness in the delivery of better
healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
to subscribe to Mobile Alerts for Quintiles.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150524005043/en/